Answers are grounded in this paper and cite their sources.
SUMMARY Objective: To compare the elimination kinetics and the effects on coagulation of two hydroxyethyl starch (HES) preparations with identical labeling. Methods: Two formulations of 6% HES 200/0.5 [HAES‐steril ™ , Fresenius Kabi, India (group A) and HESTAR‐200 ™ , Claris Lifesciences, India (group B)] were compared in a randomized, double‐blind, prospective study in 22 stroke patients receiving HES for therapeutic hemodilution over 10 days. Results: Mean in vivo molecular weight (Mw) of HES on day 6 was 98,036 ± 5631 Da in group A and 157,254 ± 5200 Da in group B ( P < 0.0001). On day 11 these values were 102,727 ± 4440 Da and 146,856 ± 9006 Da in group A and group B, respectively ( P = 0.0002). From day 2 to day 11, plasma HES concentrations were significantly higher in group B than in group A ( P < 0.05). Group A showed less thromboelastographic abnormalities. Conclusion: Two HES formulations with similar Mw and degree of substitution should not be considered equivalent based on label claims only.
No takes yet. Share an insight, caveat, or question.
Gopinath et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: